To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Three immunotherapeutic approaches have been tested in recurrent miscarriage (RM): prednisone, active immunization with allogeneic lymphocytes from the partner or third-party donors, and intravenous immunoglobulin (IvIg). The thought that allogeneic leukocyte immunization therapy (ALT) could be beneficial in RM arose from the observation that injections of paternal lymphocytes into pregnant female mice in crosses of strains with a high fetal resorption rate could decrease the resorption rate. The placebo-controlled trial (PCTs) included in the Cochrane meta-analysis of ALT were very heterogeneous with respect to the frequency of secondary RM patients. Intravenous immunoglobulin (IvIg) is prepared by extracting the IgG fraction from plasma from normal blood donors. More PCTs in the potential main target group with primary RM should be undertaken to get better documentation for the benefit and more information about the optimal doses and methods of administration and about harm effects.